Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT
暂无分享,去创建一个
K. Sułek | M. Aljurf | D. Niederwieser | J. Passweg | H. Greinix | S. Siitonen | G. Basak | I. Moiseev | P. Ronchi | A. Piekarska | Z. Perić | T. Ruutu | M. Faraci | C. Koenecke | Y. Chalandon | K. Lewandowski | F. Giglio | V. Dvirnyk | A. Rovó | O. Penack | R. Duarte | L. Friis | D. Tsakiris | P. Rzepecki | C. Peczynski | F. Scuderi | U. Wilkowojska | M. Drokov | R. Alnounou | B. Kornblit | T. Tsvetkova | Janet Bogardt | Christiane Koelper | D. Sigrist | F. Stoelzel | Randa Alnounou | Valentina Dvirnyk | Urszula Wilkowojska
[1] C. Lengerke,et al. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease , 2018, Bone Marrow Transplantation.
[2] S. Davies,et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. , 2017, Blood.
[3] C. Hofmeister,et al. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy , 2016, Bone Marrow Transplantation.
[4] K. Myers,et al. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[5] M. Tanimoto,et al. Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin , 2016, Transfusion.
[6] J. Lesesve,et al. Fragmented red cells reference range for the Sysmex XN®‐series of automated blood cell counters , 2015, International journal of laboratory hematology.
[7] J. Bay,et al. Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC , 2015, Transplantation.
[8] W. Hogan,et al. Outcomes of plasma exchange in patients with transplant‐associated thrombotic microangiopathy based on time of presentation since transplant , 2015, Journal of clinical apheresis.
[9] J. Khoury,et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. , 2014, Blood.
[10] J. González-Porras,et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients , 2013, Haematologica.
[11] S.‐H. Lee,et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes , 2012, International journal of laboratory hematology.
[12] S. Davies,et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. , 2011, Blood.
[13] T. Lecompte,et al. Evaluation of schistocyte monitoring after haematopoietic stem cell transplantation , 2011, International journal of laboratory hematology.
[14] B. Cho,et al. Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem-Cell Transplantation , 2010, Transplantation.
[15] James W. Young,et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] F. Baron,et al. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning , 2010, Bone Marrow Transplantation.
[17] C. Alpers,et al. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[18] A. Gratwohl,et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants , 2005, Bone Marrow Transplantation.
[19] D. Srivastava,et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] R. Soiffer,et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] R. Soiffer,et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] M. Czuczman,et al. Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion , 2004, Transplantation.
[23] A. Kiani,et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] J. Moake,et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. , 2007, Haematologica.